Repatha vs Leqvio: Cost, Access, and Clinical Comparison

How the Two Drugs Work: PCSK9 Antibody vs. siRNA

Repatha and Leqvio both reduce LDL cholesterol by targeting PCSK9, but through fundamentally different mechanisms. Repatha (evolocumab) is a monoclonal antibody that binds circulating PCSK9 protein in the bloodstream, preventing it from degrading LDL receptors on liver cells. Leqvio (inclisiran) is a small interfering RNA (siRNA) that enters hepatocytes and silences the gene encoding PCSK9, stopping production of the protein before it is made.

This distinction matters clinically. Repatha blocks PCSK9 after it has been synthesized and secreted, which means plasma PCSK9 levels actually rise during treatment as the blocked protein accumulates. Inclisiran prevents PCSK9 synthesis at the mRNA level, so circulating PCSK9 drops to near-undetectable concentrations 1. The downstream effect on LDL receptors is similar. Both approaches increase the number of functional LDL receptors on hepatocyte surfaces, pulling more LDL-C from the blood.

The practical difference is durability. Evolocumab's antibody is cleared from circulation in roughly 11 to 17 days, requiring injections every two weeks (140 mg) or monthly (420 mg). Inclisiran's siRNA is taken up by hepatocytes via GalNAc-conjugate targeting and persists intracellularly for months, producing LDL-C suppression that lasts approximately six months per dose 2. The GalNAc conjugation technology is what allows the twice-yearly dosing schedule that distinguishes Leqvio from all other PCSK9-targeted therapies on the market.

Neither drug has meaningful activity against lipoprotein(a), though both produce modest Lp(a) reductions in the range of 25% to 30%.

LDL-C Reduction: What the Trials Show

Both drugs lower LDL-C by approximately 50% to 60% on top of maximally tolerated statin therapy. The difference in trial design means the numbers are not directly comparable, but the magnitude is similar enough that most lipidologists consider them interchangeable for LDL lowering.

In the FOURIER trial (N=27,564), evolocumab reduced LDL-C by 59% from baseline at 48 weeks, bringing the median LDL-C from 92 mg/dL to 30 mg/dL in the treatment arm [2]. This was a large, event-driven outcomes trial enrolling patients with established atherosclerotic cardiovascular disease (ASCVD) already on statin therapy.

In the pooled ORION-10 and ORION-11 trials (combined N=3,178), inclisiran reduced LDL-C by 52.3% (ORION-10) and 49.9% (ORION-11) at day 510 compared to placebo [1]. ORION-10 enrolled patients with ASCVD, while ORION-11 included both ASCVD patients and those with ASCVD risk equivalents. The time-averaged LDL-C reduction across the dosing interval was approximately 50% for both studies.

One subtle difference: evolocumab produces its maximum LDL-C reduction within two weeks of the first injection, with levels rising slightly before each subsequent dose (the "sawtooth" pattern). Inclisiran reaches peak effect by about 60 to 90 days and maintains a relatively flat LDL-C curve between doses. For patients who are sensitive to LDL-C variability, the flatter pharmacodynamic profile of inclisiran may be preferable, though no trial has demonstrated that LDL variability itself affects outcomes in this context.

Cardiovascular Outcomes: The Critical Gap

This is where the comparison becomes asymmetric. Repatha has a completed cardiovascular outcomes trial (CVOT). Leqvio does not, as of mid-2026.

FOURIER randomized 27,564 patients with established ASCVD to evolocumab or placebo on top of statin therapy. Over a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) 2. The key secondary endpoint of cardiovascular death, MI, or stroke was reduced by 20% (HR 0.80 to 95% CI 0.73 to 0.88). No reduction in cardiovascular mortality was observed during the trial period.

The American College of Cardiology and American Heart Association 2018 cholesterol guidelines cite FOURIER as the basis for recommending PCSK9 inhibitors in patients with ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe.

Leqvio's outcomes trial, ORION-4 (N~15,000), is expected to report results in late 2026 or 2027. Until those data are available, inclisiran's cardiovascular benefit is inferred from LDL-C lowering rather than proven by direct event reduction. The Endocrine Society and multiple formulary committees have noted this distinction in their coverage determinations 3.

Dr. Steven Nissen, Cleveland Clinic's Chief Academic Officer of Cardiovascular Medicine, stated in a 2023 editorial: "We should not assume that all LDL-lowering strategies produce equivalent cardiovascular risk reduction. The Cholesterol Treatment Trialists' Collaboration has shown proportionality between LDL reduction and event reduction, but each mechanism deserves its own outcomes confirmation."

This gap matters for formulary positioning. Some payers and pharmacy benefit managers have placed Leqvio at a lower formulary tier to encourage adoption based on cost and dosing convenience, while others have restricted it to patients who have failed or are intolerant to a PCSK9 monoclonal antibody precisely because it lacks CVOT data.

Cost Comparison: List Price vs. Net Price

At wholesale acquisition cost (WAC), the two drugs are priced within a few hundred dollars of each other annually. Real-world out-of-pocket costs diverge based on insurance type, formulary tier, and copay assistance.

Repatha's WAC is approximately $514 per monthly dose, or roughly $6,168 per year for the every-two-week 140 mg regimen. Leqvio's WAC is approximately $3,250 per injection, totaling roughly $6,497 per year for the two maintenance doses (after the initial loading dose at month 3) 4. Amgen reduced Repatha's list price by approximately 60% in 2018, bringing it closer to the range that health economists had modeled as cost-effective. Novartis launched Leqvio at a price designed to match or slightly undercut Repatha's net cost after rebates.

Net prices, after rebates negotiated between manufacturers and PBMs, are not publicly disclosed. Industry estimates from the Institute for Clinical and Economic Review (ICER) suggest net annual costs for both drugs fall in the $3,500 to $5,000 range for most commercial plans. The drugs' value frameworks have converged: ICER's 2023 reassessment rated both as "low value" above $5,000/year and "intermediate value" in the $2,000 to $5,000 range based on cost-per-QALY thresholds 5.

For Medicare Part B, Leqvio has a distinct advantage. Because it is administered by a healthcare provider in-office, it is covered under Part B's buy-and-bill model rather than Part D's pharmacy benefit. This means patients pay 20% coinsurance after meeting the Part B deductible, which is often substantially less than the coverage gap (formerly "donut hole") exposure under Part D that applies to Repatha. Novartis also offers a copay assistance program covering up to $13,000 annually for commercially insured patients.

Amgen's copay card for Repatha covers the first $150 of a patient's out-of-pocket cost per fill, or provides $0 copay for eligible commercially insured patients. For uninsured patients, both manufacturers offer patient assistance programs that provide the drug at no cost to qualifying individuals.

Insurance Coverage and Prior Authorization

Both drugs require prior authorization (PA) from virtually all commercial and government payers. The criteria are similar but not identical.

Typical PA requirements for either drug include documented ASCVD or familial hypercholesterolemia (FH), LDL-C at or above 70 mg/dL (ASCVD) or 100 mg/dL (primary prevention with FH), current use of maximally tolerated statin therapy (or documented statin intolerance), and trial of ezetimibe 6.

Some plans add an additional requirement for Leqvio: documented failure of, intolerance to, or contraindication to a PCSK9 monoclonal antibody. This step-therapy requirement effectively makes Repatha (or Praluent, alirocumab) the first-line PCSK9 agent on those formularies. Express Scripts, CVS Caremark, and Optum Rx have each taken different approaches, and formulary positions shift with each contract cycle.

A 2024 analysis published in the Journal of Managed Care & Specialty Pharmacy found that PA approval rates for PCSK9-targeted therapies have improved from approximately 47% in 2017 to 72% in 2023, reflecting both simplified PA criteria and greater clinician familiarity with documentation requirements 7.

One access advantage for Leqvio is that the in-office administration model bypasses the specialty pharmacy dispensing chain entirely. Patients do not need to coordinate home delivery, manage cold storage, or remember injection schedules. The prescribing physician's office orders the drug through a specialty distributor, stores it, and administers it during a routine visit. This can reduce time-to-first-dose for patients who would otherwise face specialty pharmacy enrollment delays of two to four weeks.

Dosing, Administration, and Adherence

The dosing schedules represent the most patient-facing difference between these two therapies.

Repatha is self-administered using a prefilled syringe, autoinjector (SureClick), or on-body infusor (Pushtronex). The standard regimen is 140 mg subcutaneously every two weeks, or 420 mg monthly. Patients store the drug refrigerated and allow it to warm to room temperature before injection. The injection itself takes about 15 seconds with the autoinjector. Most patients inject into the abdomen, thigh, or upper arm.

Leqvio is administered by a healthcare provider as a 284 mg subcutaneous injection. The schedule is: day 1, day 90, then every 6 months. After the initial loading period, patients visit their provider twice a year. The drug is stored refrigerated at the provider's office.

Real-world adherence data for PCSK9 monoclonal antibodies has been disappointing. A 2022 analysis of commercial claims found that only 29% of patients prescribed a PCSK9 inhibitor remained on therapy at 24 months, with cost and injection burden cited as the top two reasons for discontinuation 8. Leqvio's twice-yearly, in-office model was designed specifically to address both barriers: the provider controls adherence by scheduling the next dose, and the Part B coverage pathway reduces out-of-pocket exposure for Medicare patients.

No head-to-head adherence trial comparing the two dosing models has been completed. The ORION-8 open-label extension showed that 90% of inclisiran-treated patients maintained LDL-C reductions below 50% through four years of follow-up, though open-label extension retention rates do not reflect real-world dropout pressures.

Safety and Tolerability

Both drugs have favorable safety profiles with low rates of serious adverse events.

In FOURIER, evolocumab's adverse event rates were similar to placebo. Injection-site reactions occurred in 2.1% of evolocumab patients vs. 1.6% on placebo. Neurocognitive events were prospectively assessed in the EBBINGHAUS substudy (N=1,974), which found no difference between evolocumab and placebo on any cognitive measure over a median of 19 months 9. New-onset diabetes rates did not differ between groups.

In ORION-10 and ORION-11, injection-site reactions were more common with inclisiran (5.0% vs. 0.7% placebo), mostly mild and transient 1. No hepatotoxicity signal emerged, with ALT and AST elevations occurring at similar rates in treatment and placebo arms. No thrombocytopenia or renal safety concerns were identified.

A theoretical concern with siRNA-based therapeutics is off-target gene silencing. Inclisiran's GalNAc conjugation provides high liver specificity, and no clinically significant off-target effects have been reported through four years of follow-up in extension studies. The European Medicines Agency's pharmacovigilance assessment through 2024 did not identify new safety signals for either drug.

Both drugs achieve very low LDL-C levels (below 25 mg/dL in some patients). Long-term safety of sustained very low LDL-C has been evaluated in FOURIER's open-label extension (FOURIER-OLE) through five years, with no excess adverse events in patients maintaining LDL-C below 20 mg/dL 10.

Which Patients Are Best Suited for Each Drug

Choosing between Repatha and Leqvio depends on several clinical and practical factors beyond raw LDL-C reduction.

Repatha may be the better fit for patients who prefer self-administration at home, those whose insurance formulary designates a PCSK9 antibody as the first-line agent, patients with established ASCVD where proven MACE reduction (FOURIER data) is a priority for shared decision-making, and those already stable on evolocumab with good adherence.

Leqvio may be the better fit for patients with a history of poor adherence to self-injectable therapies, Medicare beneficiaries who would benefit from Part B coverage rather than Part D, patients who prefer fewer injections (two per year vs. 26 per year), and those whose plan has positioned Leqvio at a lower cost-share tier than Repatha.

For patients with heterozygous familial hypercholesterolemia (HeFH), both drugs carry FDA-approved indications. Repatha also carries an FDA indication for homozygous FH (HoFH), where evolocumab 420 mg monthly produced a 31% LDL-C reduction in the TESLA Part B trial. Leqvio does not currently have an HoFH indication.

The 2022 ACC Expert Consensus Decision Pathway for nonstatin therapies does not preferentially recommend one PCSK9-targeting agent over the other, noting that selection should be individualized based on "patient preference, insurance coverage, and clinical circumstances" 11.

Switching Between Repatha and Leqvio

Patients can transition from one drug to the other. No washout period is required.

The recommended approach for switching from Repatha to Leqvio is to administer the first Leqvio dose when the next Repatha dose would have been due. Because inclisiran takes 30 to 60 days to reach full effect, LDL-C may rise transiently during the transition. Some clinicians overlap by one to two Repatha doses to bridge this gap, though this practice is not addressed in either drug's prescribing information.

Switching from Leqvio to Repatha is simpler. Because evolocumab reaches steady-state effect within 12 days, patients can start Repatha at any point after their last Leqvio dose begins to wane (typically around months 5 to 6). LDL-C monitoring four to eight weeks after the switch confirms adequate response.

The Bottom Line on Value

Both drugs cost roughly the same at list price. Both reduce LDL-C by about 50%. The clinical distinction is that Repatha has proven cardiovascular event reduction while Leqvio does not, pending ORION-4. The practical distinction is that Leqvio's twice-yearly in-office dosing removes the adherence burden and may cost less out-of-pocket for Medicare patients through Part B coverage.

For patients with commercial insurance, the choice often comes down to which drug their PBM has placed in the preferred position. For Medicare patients, Leqvio's Part B pathway is a meaningful financial advantage. For all patients, the conversation should include the fact that evolocumab's FOURIER data demonstrated a 20% reduction in the composite of CV death, MI, and stroke (HR 0.80, P<0.001), while inclisiran's outcomes data remain pending 2.

Prescribers should check each patient's formulary in real time, because PCSK9 coverage policies change at least annually with PBM contract renegotiations.